Loading…
Ultragenyx Pharmaceutical Inc. is projected to rise to $31.32 by 2027, a +20% move from its current price of $26.04. RARE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $25.34 | $26.05 | $26.77 | +0.02% |
| Aug 2 | $25.06 | $26.05 | $27.08 | +0.04% |
| Aug 3 | $24.84 | $26.06 | $27.33 | +0.06% |
| Aug 4 | $24.67 | $26.06 | $27.54 | +0.08% |
| Aug 5 | $24.51 | $26.07 | $27.72 | +0.10% |
| Aug 6 | $24.37 | $26.07 | $27.89 | +0.12% |
| Aug 7 | $24.25 | $26.08 | $28.05 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.25 | $26.08 | $28.05 | +0.15% |
| Week 2 | $23.56 | $26.12 | $28.95 | +0.29% |
| Week 3 | $23.06 | $26.15 | $29.67 | +0.44% |
| Week 4 | $22.64 | $26.19 | $30.29 | +0.58% |
| Week 5 | $22.29 | $26.23 | $30.86 | +0.73% |
| Week 6 | $21.98 | $26.27 | $31.39 | +0.87% |
| Week 7 | $21.70 | $26.31 | $31.89 | +1.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Its product candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona.
Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc. (RARE) is currently trading at $25.00. It holds a market cap of $2.46B and is ranked 1895. The current price sits within a landscape where longer-term forecasts project a bullish path, with the average price forecast rising over time from $25.00 in 2026 to $274.68 in 2050, and with the 2050 max forecast reaching $505.60.
This trajectory includes a range of annual average forecasts and progressively larger potential upside, culminating in an estimated ROI of up to 998.7% by 2050.
A major floor 30.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 37.7% above — a clean break opens room to run.
A major ceiling 53.0% above — clearing it would confirm fresh momentum.
Key RARE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RARE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $26.16 | Sell | $26.24 | Sell |
| MA 10 | $27.19 | Sell | $27.32 | Sell |
| MA 20 | $30.26 | Sell | $28.41 | Sell |
| MA 50 | $27.36 | Sell | $27.85 | Sell |
| MA 100 | $25.31 | Buy | $26.88 | Sell |
| MA 200 | $27.05 | Sell | $27.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.68 | Neutral |
| Stoch RSI (14) | 19.83 | Buy |
| CCI (20) | -91.52 | Neutral |
| Williams %R (14) | -87.35 | Info |
| MACD (12,26,9) | -0.83 | Sell |
| ROC (12) | -18.70 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 12.65 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -3.29 | Sell |
| Ultimate (7,14,28) | 22.68 | Buy |
| Momentum (10) | -4.18 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 25.25 | Buy |
| ADX (14) | 27.26 | Sell |
| ATR (14) | 0.77 | Info |
The 30-day technical picture is mixed but leans toward a neutral to cautious stance. The 14-day RSI is 30, indicating a neutral position on near-term momentum. The 50-day simple moving average is $27.32 and the 200-day simple moving average is $27.08, with the stock trading around the $25.00 level.
Key near-term support is $24.85 and resistance is $35.87. Over the last 30 days, the price has traded in a range from $20.92 to $29.88, reflecting notable volatility (annualized volatility ~50%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.50 | $26.04 | $32.48 | 0% | Neutral | |
| $24.96 | $31.32 | $41.57 | +20% | Bullish | |
| $28.98 | $37.42 | $51.57 | +44% | Bullish | |
| $37.14 | $49.09 | $69.66 | +89% | Bullish | |
| $42.26 | $57.02 | $82.95 | +119% | Bullish | |
| $43.58 | $59.93 | $89.07 | +130% | Bullish | |
| $48.26 | $67.53 | $102.32 | +159% | Bullish | |
| $51.14 | $72.75 | $112.17 | +179% | Bullish | |
| $53.88 | $77.85 | $121.97 | +199% | Bullish | |
| $62.48 | $91.63 | $145.71 | +252% | Bullish | |
| $92.58 | $145.30 | $245.88 | +458% | Bullish | |
| $188.66 | $332.73 | $616.40 | +11.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.50 | $26.04 | $30.37 | +0.00% |
| August 2026 | $22.04 | $25.87 | $31.07 | -0.67% |
| September 2026 | $22.42 | $26.54 | $32.31 | +2.60% |
| October 2026 | $22.84 | $27.22 | $33.50 | +2.58% |
| November 2026 | $22.17 | $26.57 | $32.98 | -2.41% |
| December 2026 | $21.56 | $25.97 | $32.48 | -2.26% |
Click any year to see its month-by-month RARE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RARE is projected to trade between $18.50 and $32.48, averaging $26.04 — a potential gain of 0% from today's $26.04. A consolidation phase looks the most probable path here.
Ultragenyx Pharmaceutical Inc.'s 2027 outlook centres on $31.32, within a $24.96 to $41.57 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. Momentum favours further upside here.
By 2028, RARE could reach as high as $51.57, with a base case around $37.42 and support toward $28.98 — roughly +44% from $26.04. Buyers look set to stay in control over this stretch.
Expect RARE to range from $37.14 to $69.66 through 2029. The $49.09 average target implies a +89% move from current prices. That is up +31% on the projected 2028 average. Momentum favours further upside here.
The RARE price prediction for 2030 points to an average of $57.02 (low $42.26, high $82.95) — a potential gain of +119% on today's $26.04. Buyers look set to stay in control over this stretch.
In 2031, RARE is projected to trade between $43.58 and $89.07, averaging $59.93 — a potential gain of +130% from today's $26.04. That is up +5% on the projected 2030 average. Momentum favours further upside here.
Ultragenyx Pharmaceutical Inc.'s 2032 outlook centres on $67.53, within a $48.26 to $102.32 range. That is up +13% on the projected 2031 average. That marks a +159% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, RARE could reach as high as $112.17, with a base case around $72.75 and support toward $51.14 — roughly +179% from $26.04. Momentum favours further upside here.
Expect RARE to range from $53.88 to $121.97 through 2034. The $77.85 average target implies a +199% move from current prices. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The RARE price prediction for 2035 points to an average of $91.63 (low $62.48, high $145.71) — a potential gain of +252% on today's $26.04. Momentum favours further upside here.
In 2040, RARE is projected to trade between $92.58 and $245.88, averaging $145.30 — a potential gain of +458% from today's $26.04. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ultragenyx Pharmaceutical Inc.'s 2050 outlook centres on $332.73, within a $188.66 to $616.40 range. That is up +129% on the projected 2040 average. That marks a +11.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in RARE today (≈ 38.402458 RARE) could be worth
$12,777.62
+$11,777.62 (+1178%) by 2050 · US Dollar
Based on the average projected RARE price of $332.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RAREwould be worth at today's price.
$1,000 invested in RARE on Jul 30, 2025 (≈ 36.845985 RARE) would be worth
$959.47
-$40.53 (-4.1%) today · 0.96× · US Dollar
Based on a RARE entry price of $27.14 vs. today's $26.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.02 | $963.73 | -3.6% |
| 1 month ago | $33.39 | $779.87 | -22.0% |
| 3 months ago | $24.77 | $1,051.27 | +5.1% |
| 6 months ago | $24.07 | $1,081.84 | +8.2% |
| 1 year ago | $27.14 | $959.47 | -4.1% |
| All time (5.0y) ago | $80.84 | $322.12 | -67.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RARE forecast.
Our base-case forecast reaches $52.00 around 2030.
Implied market cap at $52.00: $5.12B
The multi-year forecast shows a bullish trajectory after a neutral near term. In 2026 the min/avg/max forecast are $18.50/$25.00/$30.98 with a 0% ROI and NEUTRAL sentiment. In 2027 the min/avg/max forecast are $23.47/$29.41/$38.94 with a 17.6% ROI and NEUTRAL sentiment.
By 2028 the min/avg/max forecast are $26.71/$34.41/$47.30 with a 37.6% ROI and BULLISH sentiment, followed by 2029 at $33.86/$44.65/$63.17 with 78.6% ROI and BULLISH sentiment. The 2030 forecast shows $38.29/$51.52/$74.69 with a 106.1% ROI and BULLISH sentiment, and the path continues higher through 2031 ($39.17/$53.68/$79.48; 114.7%), 2032 ($43.08/$60.07/$90.65; 140.3%), 2033 ($45.31/$64.20/$98.57; 156.8%), 2034 ($47.19/$67.89/$105.89; 171.6%), and 2035 ($54.18/$79.09/$125.19; 216.4%). The forecast then extends to 2040 with $79.00/$123.23/$207.41 and 392.9% ROI, and to 2050 with $157.17/$274.68/$505.60 and 998.7% ROI, all with a bullish sentiment.
These figures illustrate a gradual to strong long‑term upside, though they remain estimates and are not guarantees.
Tap a question to reveal the answer.
The 2027 forecast shows min $23.47, avg $29.41, max $38.94 with a 17.6% ROI and NEUTRAL sentiment.
The long-term forecast indicates bullish potential, with the average price rising to $274.68 by 2050 and ROI up to 998.7% in 2050. Early years show NEUTRAL sentiment (e.g., 2026: 0% ROI; 2027: 17.6% ROI).
Yes. The 2034 max price is $105.89, which surpasses $100.
Current price is $25.00 and market cap is $2.46B; the rank is 1895.
RSI(14) is 30; SMA50 is $27.32; SMA200 is $27.08; support is $24.85 and resistance is $35.87; the 30-day range is $20.92 to $29.88.
Ultragenyx Pharmaceutical Inc. Community Discussion
0Share your Ultragenyx Pharmaceutical Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.